8-K: Citius Pharmaceuticals Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals announced its fiscal first quarter 2025 financial results, highlighting progress in commercializing LYMPHIR and securing additional financing.

Summary

• Citius Pharmaceuticals reported its financial results for the first quarter of fiscal year 2025, which ended December 31, 2024.
• The company is advancing operational readiness for the commercial launch of LYMPHIR in the first half of 2025.
• A new permanent J-code, J9161, for LYMPHIR was secured with an expected effective date of April 1, 2025.
• Preliminary results from a Phase I clinical trial of pembrolizumab and LYMPHIR in patients with recurrent solid tumors were announced.
• The company supported the expansion of a Phase I clinical trial at the University of Minnesota to evaluate denileukin diftitox administration prior to CAR-T therapies.
• Citius Pharma engaged with the FDA to clarify development paths for Mino-Lok and Halo-Lido.
• Strategic and financing initiatives were advanced, including Jefferies being engaged as a financial advisor for Citius Oncology.
• Registered direct offerings and at-the-market facility sales generated $6.5 million in gross proceeds.
• A 1-for-25 reverse stock split was executed on November 25, 2024.
• The company regained compliance with Nasdaq's $1.00 per share requirement on December 18, 2024.
• Cash and cash equivalents totaled $1.1 million as of December 31, 2024.
• R&D expenses were $2.1 million for the quarter, compared to $2.6 million in the prior year.
• G&A expenses were $5.4 million, up from $3.7 million in the prior year.
• Stock-based compensation expense was $2.5 million, compared to $3.1 million in the prior year.
• The net loss was $10.3 million, or ($1.30) per share, compared to a net loss of $9.2 million, or ($1.45) per share, in the prior year.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is progressing with LYMPHIR's commercialization and has secured additional funding, the increased net loss and low cash reserves raise concerns.

Positives

• LYMPHIR is nearing commercial launch, expected in the first half of 2025.
• The company secured a new J-code for LYMPHIR, which should facilitate reimbursement.
• Preliminary results from the Phase I trial of LYMPHIR with pembrolizumab are promising.
• Citius Pharma successfully raised $6.5 million through equity offerings.
• The company regained compliance with Nasdaq's listing requirements.

Negatives

• The company's cash and cash equivalents are low at $1.1 million as of December 31, 2024.
• The net loss increased to $10.3 million, or ($1.30) per share, for the quarter ended December 31, 2024.
• General and administrative expenses increased significantly due to pre-launch sales and marketing activities.

Risks

• The company needs substantial additional funds to continue operations.
• The company's ability to commercialize LYMPHIR and other product candidates is subject to market acceptance and regulatory approvals.
• The company depends on third-party suppliers and strategic agreements.
• Uncertainties exist regarding preclinical and clinical testing.

Future Outlook

The company anticipates launching LYMPHIR in the first half of 2025 and is evaluating multiple options to strengthen its financial position.

Management Comments

• Securing the necessary financing to support our key programs remains a top priority, and we are evaluating multiple options to strengthen our financial position, stated Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals.
• We are making significant progress in our preparations for the anticipated launch of LYMPHIR in the first half of 2025, positioning us to bring this important therapy to patients while creating long-term value for our shareholders, added Mazur.

Industry Context

Citius Pharma is focused on critical care products, with LYMPHIR targeting cutaneous T-cell lymphoma, a niche market. The company's engagement with the FDA and ongoing clinical trials are typical for biopharmaceutical companies in this sector.

Comparison to Industry Standards

• Given the stage of Citius's lead product, LYMPHIR, comparisons can be drawn to companies like Seagen (now part of Pfizer) which also developed and commercialized antibody-drug conjugates for cancer.
• The R&D spending of $2.1 million is relatively low compared to larger pharmaceutical companies but is typical for a company of Citius's size and stage of development.
• The net loss of $10.3 million is also within the expected range for a company investing in clinical trials and preparing for a product launch.

Stakeholder Impact

• Shareholders may be impacted by the reverse stock split and the need for additional capital.
• Patients with cutaneous T-cell lymphoma could benefit from the potential launch of LYMPHIR.
• Employees are affected by the company's financial performance and strategic decisions.

Next Steps

• Advance operational readiness for the commercial launch of LYMPHIR in the first half of 2025.
• Continue engaging with the FDA to clarify development paths for pipeline assets Mino-Lok and Halo-Lido.
• Evaluate strategic alternatives for Citius Oncology to maximize shareholder value.
• Secure additional financing to support key programs.

Key Dates